Empery Asset Management’s NeuroSense Therapeutics Warrant NRSNW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.3K Sell
95,499
-4,903
-5% -$349 ﹤0.01% 32
2026
Q2
$6.32K Hold
100,402
– – 0.01% 31
2026
Q1
$20.1K Hold
100,402
– – 0.02% 26
2025
Q4
$36.1K Buy
+100,402
New +$35.7K 0.03% 23
2022
Q3
$47K Hold
160,000
– – 0.28% 41
2022
Q2
$82K Hold
160,000
– – 0.44% 22
2022
Q1
$96K Hold
160,000
– – 0.45% 31
2021
Q4
$15K Buy
+160,000
New +$143K 0.03% 68

Other funds holding NRSNW

Empery Asset Management's NRSNW Position: Q3 2026 in Review

Empery Asset Management reduced its NeuroSense Therapeutics Warrant (NRSNW) stake by 4.9% in Q3 2026, selling an estimated $349 and leaving 95,499 shares worth $4.3K. The position accounts for ﹤0.01% of the portfolio, ranked #32.

Empery Asset Management first reported a position in NRSNW in Q4 2021 and has held it in 8 quarters since. The position peaked at $96K in Q1 2022. 3 funds tracked by Wall St. Rank hold NRSNW as of Q3 2026.

  • Empery Asset Management held 95,499 shares of NeuroSense Therapeutics Warrant worth $4.3K as of Q3 2026.
  • Empery Asset Management sold 4,903 NeuroSense Therapeutics Warrant shares in Q3 2026, an estimated $349.
  • NeuroSense Therapeutics Warrant made up ﹤0.01% of Empery Asset Management's portfolio in Q3 2026, its #32 holding.
  • Empery Asset Management first reported a position in NeuroSense Therapeutics Warrant in Q4 2021 and has held it in 8 quarters since.
  • Empery Asset Management's NeuroSense Therapeutics Warrant position peaked at $96K in Q1 2022.
  • 3 funds tracked by Wall St. Rank held NeuroSense Therapeutics Warrant as of Q3 2026.

Based on Empery Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.